Oral mucositis

J.E. Raber-Durlacher; S. Elad; A. Barasch

doi:10.1016/j.oraloncology.2010.03.012

Oral mucositis

J.E. Raber-Durlacher, S. Elad, A. Barasch

Research output: Contribution to Journal › Article › Academic › peer-review

Abstract

Mucosal damage is one of the most common adverse effects of radiotherapy and of cytotoxic therapy for cancer. With prevalence between 10% and 100%, depending of the cytotoxic regimen and patient-associated variables, this morbid condition represents a significant problem in oncology. In this paper we address oral mucositis and discuss its pathobiology, risk factors, impact and management in view of the most recent evidence. Despite of clear progress and the development of clinical guidelines, what we currently have to offer to patients to manage mucositis and oropharyngeal pain is still inadequate. Expansion of the knowledge of the pathogenesis of mucositis as well as a better insight into individual risk factors will provide opportunities to improve management strategies.

Original language	English
Pages (from-to)	452-456
Journal	Oral Oncology
Volume	46
Issue number	6
DOIs	https://doi.org/10.1016/j.oraloncology.2010.03.012
Publication status	Published - 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.oraloncology.2010.03.012

Persistent URL (handle)

Persistent link

Cite this

@article{a3e2d4f3b91e4f75b2021dee6b90f063,

title = "Oral mucositis",

abstract = "Mucosal damage is one of the most common adverse effects of radiotherapy and of cytotoxic therapy for cancer. With prevalence between 10% and 100%, depending of the cytotoxic regimen and patient-associated variables, this morbid condition represents a significant problem in oncology. In this paper we address oral mucositis and discuss its pathobiology, risk factors, impact and management in view of the most recent evidence. Despite of clear progress and the development of clinical guidelines, what we currently have to offer to patients to manage mucositis and oropharyngeal pain is still inadequate. Expansion of the knowledge of the pathogenesis of mucositis as well as a better insight into individual risk factors will provide opportunities to improve management strategies.",

author = "J.E. Raber-Durlacher and S. Elad and A. Barasch",

year = "2010",

doi = "10.1016/j.oraloncology.2010.03.012",

language = "English",

volume = "46",

pages = "452--456",

journal = "Oral Oncology",

issn = "1368-8375",

publisher = "Elsevier Ltd",

number = "6",

}

TY - JOUR

T1 - Oral mucositis

AU - Raber-Durlacher, J.E.

AU - Elad, S.

AU - Barasch, A.

PY - 2010

Y1 - 2010

N2 - Mucosal damage is one of the most common adverse effects of radiotherapy and of cytotoxic therapy for cancer. With prevalence between 10% and 100%, depending of the cytotoxic regimen and patient-associated variables, this morbid condition represents a significant problem in oncology. In this paper we address oral mucositis and discuss its pathobiology, risk factors, impact and management in view of the most recent evidence. Despite of clear progress and the development of clinical guidelines, what we currently have to offer to patients to manage mucositis and oropharyngeal pain is still inadequate. Expansion of the knowledge of the pathogenesis of mucositis as well as a better insight into individual risk factors will provide opportunities to improve management strategies.

AB - Mucosal damage is one of the most common adverse effects of radiotherapy and of cytotoxic therapy for cancer. With prevalence between 10% and 100%, depending of the cytotoxic regimen and patient-associated variables, this morbid condition represents a significant problem in oncology. In this paper we address oral mucositis and discuss its pathobiology, risk factors, impact and management in view of the most recent evidence. Despite of clear progress and the development of clinical guidelines, what we currently have to offer to patients to manage mucositis and oropharyngeal pain is still inadequate. Expansion of the knowledge of the pathogenesis of mucositis as well as a better insight into individual risk factors will provide opportunities to improve management strategies.

U2 - 10.1016/j.oraloncology.2010.03.012

DO - 10.1016/j.oraloncology.2010.03.012

M3 - Article

SN - 1368-8375

VL - 46

SP - 452

EP - 456

JO - Oral Oncology

JF - Oral Oncology

IS - 6

ER -

Oral mucositis

Abstract

UN SDGs

Access to Document

Persistent URL (handle)

Fingerprint

Cite this